Benitec Biopharma (BNTC) Net Income towards Common Stockholders: 2019-2025
Historic Net Income towards Common Stockholders for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$8.8 million.
- Benitec Biopharma's Net Income towards Common Stockholders fell 86.55% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$37.9 million, marking a year-over-year decrease of 69.50%. This contributed to the annual value of -$37.9 million for FY2025, which is 69.50% down from last year.
- According to the latest figures from Q2 2025, Benitec Biopharma's Net Income towards Common Stockholders is -$8.8 million, which was up 39.28% from -$14.5 million recorded in Q1 2025.
- In the past 5 years, Benitec Biopharma's Net Income towards Common Stockholders ranged from a high of -$3.5 million in Q1 2022 and a low of -$14.5 million during Q1 2025.
- Over the past 3 years, Benitec Biopharma's median Net Income towards Common Stockholders value was -$5.8 million (recorded in 2023), while the average stood at -$6.9 million.
- In the last 5 years, Benitec Biopharma's Net Income towards Common Stockholders grew by 23.03% in 2024 and then slumped by 238.89% in 2025.
- Benitec Biopharma's Net Income towards Common Stockholders (Quarterly) stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then fell by 20.98% to -$6.8 million in 2023, then tumbled by 40.51% to -$9.6 million in 2024, then crashed by 86.55% to -$8.8 million in 2025.
- Its last three reported values are -$8.8 million in Q2 2025, -$14.5 million for Q1 2025, and -$9.6 million during Q4 2024.